Christopher Wright
Directeur/Membre du Conseil chez ALKERMES PLC
Fortune : 228 782 $ au 31/05/2024
Profil
Christopher I.
Wright is an Independent Director at Alkermes Plc and the Chief Medical Officer at Ring Therapeutics, Inc. He previously held positions as the SVP-Global Medicines Development & Medical Affairs at Vertex Pharmaceuticals, Inc., the Chief Development Officer & SVP-Global Development at Ironwood Pharmaceuticals, Inc., an Associate Professor at Harvard Medical School, the Chief Medical Officer & Senior Vice President at Axcella Health, Inc., the Chief Medical Officer & Senior Vice President at Cyclerion Therapeutics, Inc., and the Chief Medical Officer at Aavantibio, Inc. Dr. Wright received his undergraduate degree from Harvard University and his doctorate from Vrije Universiteit Amsterdam.
He also holds graduate and doctorate degrees from Harvard Medical School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 08/06/2024 | 9 777 ( 0,01% ) | 228 782 $ | 31/05/2024 |
Postes actifs de Christopher Wright
| Sociétés | Poste | Début |
|---|---|---|
| ALKERMES PLC | Directeur/Membre du Conseil | 24/05/2022 |
Ring Therapeutics, Inc.
 Ring Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ring Therapeutics, Inc. engages in the development of a gene therapy platform. Its Anellovector platform provides tissue specifities benefitting from the inherent diversity of tropism afforded by the commensal virome. The company was founded in 2000 and is headquartered in Cambridge, MA. | Directeur Technique/Scientifique/R&D | - |
Anciens postes connus de Christopher Wright
| Sociétés | Poste | Fin |
|---|---|---|
| CYCLERION THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 26/03/2021 |
Aavantibio, Inc.
 Aavantibio, Inc. BiotechnologyHealth Technology Aavantibio, Inc. engages in developing gene therapies. The company was founded by Barry Byrne and Manuela Corti and is headquartered in Gainesville, FL. | Directeur Technique/Scientifique/R&D | - |
| Harvard Medical School | Corporate Officer/Principal | - |
| IRONWOOD PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
| AXCA HEALPAR | Directeur Technique/Scientifique/R&D | - |
Formation de Christopher Wright
| Harvard University | Undergraduate Degree |
| Harvard Medical School | Doctorate Degree |
| Vrije Universiteit Amsterdam | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| AXCA HEALPAR | Health Technology |
| IRONWOOD PHARMACEUTICALS, INC. | Health Technology |
| CYCLERION THERAPEUTICS, INC. | Health Technology |
| ALKERMES PLC | Health Technology |
| Entreprise privées | 2 |
|---|---|
Aavantibio, Inc.
Aavantibio, Inc. BiotechnologyHealth Technology Aavantibio, Inc. engages in developing gene therapies. The company was founded by Barry Byrne and Manuela Corti and is headquartered in Gainesville, FL. | Health Technology |
Ring Therapeutics, Inc.
Ring Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ring Therapeutics, Inc. engages in the development of a gene therapy platform. Its Anellovector platform provides tissue specifities benefitting from the inherent diversity of tropism afforded by the commensal virome. The company was founded in 2000 and is headquartered in Cambridge, MA. | Health Technology |
